Parallax Health Sciences Inc. reported unaudited consolidated financial results for the three and nine months ended September 30, 2018. Total revenues from continuing operations for the three months ended September 30, 2018 were $990, compared with total revenues of $30,139 for the third quarter of 2017. Net operating loss from continuing operations for the third quarter of 2018 was $2.1 million, or $0.01 per diluted share, compared with a net operating loss from continuing operations for the third quarter of 2017 of $2.3 million, or $0.1 per diluted share. The $224,275 improvement in operating loss from continuing operations is primarily due to a reduction in general and administrative expenses. Net income from continuing operations for the three months ended September 30, 2018 was $25.6 million, or $0.12 per diluted common share, compared with a net loss of $3.9 million, or $0.03 per share, for the same period last year. Net income was $25.7 million compared to net loss of $4.706 million a year ago. Total revenues for the nine months ended September 30, 2018 were $10,749, compared to total revenues from continuing operations of $70,641 in the year-ago period. The Company recorded a net operating loss from continuing operations of $5.1 million, or $0.03 per share, in the nine months ended September 30, 2018, compared with a net operating loss of $3.2 million or $0.02 per share, for the same period last year. Net income from continuing operations for the nine months ended September 30, 2018 was $19.077 million, or $0.093 per diluted common share, compared with a net loss of $7.849 million, or $0.046 per share, for the same period last year. Net income was $18.252 million compared to net loss of $10.121 million a year ago.